

# CDC Malaria Vaccine Research Activities

Presentation to FMVCC  
7 January 2011

Mary Hamel, M.D.  
Malaria Branch, CDC

# CDC Malaria Vaccine Research Activities

- Conduct clinical trials in the field
- Facilitate vaccine development by conducting non-human primate preclinical evaluations of GLP/GMP vaccines
- Define correlates of immunity biomarkers

# Conduct Clinical Trials

- Focus on phase II – IV clinical trials
  - Vaccines that are likely to have a public health impact
  - Access to large populations through partners in Africa, Asia and the Americas
    - Maintain demographic surveillance systems which include large populations

# Conduct Clinical Trials

- RTS,S trial in Kisumu, Kenya
  - Expect enrollment for both age-groups (5-17 months and 6-12 weeks) to be complete in February 2011
  - Involved in a sub-study to measure immunogenicity and safety of the RTS,S/AS01E vaccine in HIV infected children
  - Will participate in an extension study to measure longer-term effect of the vaccine

# Non-Human Primate Facility

- Facilitate vaccine development by conducting non-human primate preclinical evaluations of GLP/GMP vaccines
  - Blood stage vaccines (*P. falciparum* and *P. vivax*)
  - Pre-erythrocytic vaccines (*P. falciparum* and *P. vivax*)
  - Transmission blocking vaccines (*P. vivax*)

# Define Biomarkers for Correlates of Immunity

- Members of OPTIMALVAC consortium
  - “Initiative on Optimizing Malaria Vaccine Lab Assays Evaluations”
    - sponsored by EMVI and WHO
  - Collaborating to standardize blood stage immunological functional assays